Cariprazine, A Broad-Spectrum Antipsychotic for the Treatment of Schizophrenia: Pharmacology, Efficacy, and Safety

por Laszlovszky, István, Barabássy, Ágota, Németh, György
Publicado 2021

Potential Mechanisms for Why Not All Antipsychotics Are Able to Occupy Dopamine D(3) Receptors in the Brain in vivo

por Kiss, Béla, Krámos, Balázs, Laszlovszky, István
Publicado 2022

Comment on: “Clinical Pharmacokinetics of Atypical Antipsychotics: An Update”

por Periclou, Antonia, Riccobene, Todd, Kapás, Margit, Laszlovszky, István
Publicado 2019

Cariprazine in the treatment of schizophrenia: a proof-of-concept trial

por Durgam, Suresh, Litman, Robert E., Papadakis, Kelly, Li, Dayong, Németh, György, Laszlovszky, István
Publicado 2016

Safety and tolerability of cariprazine in patients with acute exacerbation of schizophrenia: a pooled analysis of four phase II/III randomized, double-blind, placebo-controlled stu...

por Earley, Willie, Durgam, Suresh, Lu, Kaifeng, Laszlovszky, István, Debelle, Marc, Kane, John M.
Publicado 2017

Efficacy of adjunctive low-dose cariprazine in major depressive disorder: a randomized, double-blind, placebo-controlled trial

por Fava, Maurizio, Durgam, Suresh, Earley, Willie, Lu, Kaifeng, Hayes, Robert, Laszlovszky, István, Németh, György
Publicado 2018

Global improvement with cariprazine in the treatment of bipolar I disorder and schizophrenia: A pooled post hoc analysis

por Durgam, Suresh, Earley, Willie, Lu, Kaifeng, Németh, György, Laszlovszky, István, Volk, Stephen, Litman, Robert E.
Publicado 2017

Safety and Tolerability of Cariprazine in Patients with Schizophrenia: A Pooled Analysis of Eight Phase II/III Studies

por Barabássy, Ágota, Sebe, Barbara, Acsai, Károly, Laszlovszky, István, Szatmári, Balázs, Earley, Willie R, Németh, György
Publicado 2021

Cariprazine Safety in Adolescents and the Elderly: Analyses of Clinical Study Data

por Szatmári, Balázs, Barabássy, Ágota, Harsányi, Judit, Laszlovszky, István, Sebe, Barbara, Gál, Mónika, Shiragami, Kazushi, Németh, György
Publicado 2020

Neuronal Dopamine D3 Receptors: Translational Implications for Preclinical Research and CNS Disorders

por Kiss, Béla, Laszlovszky, István, Krámos, Balázs, Visegrády, András, Bobok, Amrita, Lévay, György, Lendvai, Balázs, Román, Viktor
Publicado 2021

Safety and tolerability of cariprazine in the long-term treatment of schizophrenia: results from a 48-week, single-arm, open-label extension study

por Durgam, Suresh, Greenberg, William M., Li, Dayong, Lu, Kaifeng, Laszlovszky, Istvan, Nemeth, Gyorgy, Migliore, Raffaele, Volk, Stephen
Publicado 2016

What Is the Minimum Clinically Important Change in Negative Symptoms of Schizophrenia? PANSS Based Post-hoc Analyses of a Phase III Clinical Trial

por Czobor, Pál, Sebe, Barbara, Acsai, Károly, Barabássy, Ágota, Laszlovszky, István, Németh, György, Furukawa, Toshi A., Leucht, Stefan
Publicado 2022

The safety and tolerability of cariprazine in long-term treatment of schizophrenia: a post hoc pooled analysis

por Nasrallah, Henry A., Earley, Willie, Cutler, Andrew J., Wang, Yao, Lu, Kaifeng, Laszlovszky, István, Németh, György, Durgam, Suresh
Publicado 2017

Linking PANSS negative symptom scores with the Clinical Global Impressions Scale: understanding negative symptom scores in schizophrenia

por Leucht, Stefan, Barabássy, Ágota, Laszlovszky, István, Szatmári, Balázs, Acsai, Károly, Szalai, Erzsébet, Harsányi, Judit, Earley, Willie, Németh, György
Publicado 2019

Disentangling the symptoms of schizophrenia: Network analysis in acute phase patients and in patients with predominant negative symptoms

por Demyttenaere, Koen, Leenaerts, Nicolas, Acsai, Károly, Sebe, Barbara, Laszlovszky, István, Barabássy, Ágota, Fonticoli, Laura, Szatmári, Balázs, Earley, Willie, Németh, György, Correll, Christoph U.
Publicado 2021

Preclinical pharmacodynamic and pharmacokinetic characterization of the major metabolites of cariprazine

por Kiss, Béla, Némethy, Zsolt, Fazekas, Károly, Kurkó, Dalma, Gyertyán, István, Sághy, Katalin, Laszlovszky, István, Farkas, Bence, Kirschner, Norbert, Bolf-Terjéki, Etelka, Balázs, Ottilia, Lendvai, Balázs
Publicado 2019

Preferential binding to dopamine D(3) over D(2) receptors by cariprazine in patients with schizophrenia using PET with the D(3)/D(2) receptor ligand [(11)C]-(+)-PHNO

por Girgis, Ragy R., Slifstein, Mark, D’Souza, Deepak, Lee, Yih, Periclou, Antonia, Ghahramani, Parviz, Laszlovszky, István, Durgam, Suresh, Adham, Nika, Nabulsi, Nabeel, Huang, Yiyun, Carson, Richard E., Kiss, Béla, Kapás, Margit, Abi-Dargham, Anissa, Rakhit, Ashok
Publicado 2016